Alexander A. Volkov
Research Subjects
Alexander A. Volkov has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Александр Валерьевич Султанбаев
Bashkir State Medical University; Republican Clinical Oncology Dispensary
3 shared publications - Ainur F. Nasretdinov
Republican Clinical Oncology Dispensary
2 shared publications - Irina A. Menshikova
Bashkir State Medical University
2 shared publications - Konstantin V. Menshikov
Republican Clinical Oncology Dispensary; Bashkir State Medical University
2 shared publications - Nadezhda I. Sultanbaeva
Republican Clinical Oncology Dispensary
2 shared publications - Shamil I. Musin
Republican Clinical Oncology Dispensary, Ufa, Russia
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 21,p. 147-154
Cholangiocarcinoma: A clinical case of long-lasting response to immunochemotherapy
Cholangiocellular carcinoma is a heterogeneous group of malignant neoplasms of the biliary tract. It accounts for approximately 3% of all gastrointestinal tumors and is the second most common primary liver tumor after hepatocellular carcinoma. Surgery is the only cure. Surgical treatments are among the most complex in hepatopancreatobiliary surgery. Standard first-line therapy with gemcitabine-based chemotherapy has demonstrated a modest improvement in survival in patients with advanced cholangiocellular carcinoma. Despite its role as the cornerstone of first-line therapy, chemotherapy produces suboptimal response rates, and overall survival highlights the urgent need for improved therapeutic strategies. The TOPAZ-1 trial, which included an immuno-oncology agent, demonstrated an improvement in overall survival. In the case described above, the patient first presented for this condition in 2022. After diagnosis verification, chemoembolization and surgical treatment were performed. Disease progression began in 2023. Based on the progression, chemotherapy in combination with durvalumab was initiated. In the case of local progression, a course of stereotactic radiotherapy was administered. This clinical case demonstrates the results of combining systemic therapy and local control methods. Progression-free survival with durvalumab therapy was 26 months. Thus, this option demonstrated the potential of modern immunochemotherapy and stereotactic radiotherapy.
- 1 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 21,p. 147-154
Open AccessCholangiocarcinoma: A clinical case of long-lasting response to immunochemotherapy
Cholangiocellular carcinoma is a heterogeneous group of malignant neoplasms of the biliary tract. It accounts for approximately 3% of all gastrointestinal tumors and is the second most common primary liver tumor after hepatocellular carcinoma. Surgery is the only cure. Surgical treatments are among the most complex in hepatopancreatobiliary surgery. Standard first-line therapy with gemcitabine-based chemotherapy has demonstrated a modest improvement in survival in patients with advanced cholangiocellular carcinoma. Despite its role as the cornerstone of first-line therapy, chemotherapy produces suboptimal response rates, and overall survival highlights the urgent need for improved therapeutic strategies. The TOPAZ-1 trial, which included an immuno-oncology agent, demonstrated an improvement in overall survival. In the case described above, the patient first presented for this condition in 2022. After diagnosis verification, chemoembolization and surgical treatment were performed. Disease progression began in 2023. Based on the progression, chemotherapy in combination with durvalumab was initiated. In the case of local progression, a course of stereotactic radiotherapy was administered. This clinical case demonstrates the results of combining systemic therapy and local control methods. Progression-free survival with durvalumab therapy was 26 months. Thus, this option demonstrated the potential of modern immunochemotherapy and stereotactic radiotherapy.
- Open Access
- 1 April 2025
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 6, 1002305
Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma
The combination of lenvatinib and pembrolizumab (Len + Pembro) demonstrated significant efficacy in the phase 3 CLEAR study for metastatic renal cell carcinoma (RCC). However, poor-risk patients represented only a small proportion of the trial population. This multicenter retrospective cohort study assessed the real-world efficacy and safety of Len + Pembro in patients with clear-cell metastatic RCC and intermediate or poor International Metastatic RCC Database Consortium risk. Outcomes included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Sixty patients were analyzed, with a median age of 56 years. Poor risk was identified in 53% of patients, and 90% had metastases to ≥ 2 organs. ORR was 48.33%, disease control rate was 86.7%, and median PFS was 19.0 months. Grade ≥ 3 adverse events occurred in 25% of patients, with 33.3% requiring lenvatinib dose reductions. Lenvatinib plus pembrolizumab demonstrated robust efficacy and a manageable safety profile in a real-world population with advanced disease and poor-risk features, consistent with outcomes reported in clinical trials.
- 1 April 2025
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 6, 1002305
Open AccessReal-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma
The combination of lenvatinib and pembrolizumab (Len + Pembro) demonstrated significant efficacy in the phase 3 CLEAR study for metastatic renal cell carcinoma (RCC). However, poor-risk patients represented only a small proportion of the trial population. This multicenter retrospective cohort study assessed the real-world efficacy and safety of Len + Pembro in patients with clear-cell metastatic RCC and intermediate or poor International Metastatic RCC Database Consortium risk. Outcomes included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Sixty patients were analyzed, with a median age of 56 years. Poor risk was identified in 53% of patients, and 90% had metastases to ≥ 2 organs. ORR was 48.33%, disease control rate was 86.7%, and median PFS was 19.0 months. Grade ≥ 3 adverse events occurred in 25% of patients, with 33.3% requiring lenvatinib dose reductions. Lenvatinib plus pembrolizumab demonstrated robust efficacy and a manageable safety profile in a real-world population with advanced disease and poor-risk features, consistent with outcomes reported in clinical trials.
- Open Access
- 25 July 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 124-130
The role of G-CSF in the prevention of cytostaticassociated adverse events during antitumor drug therapy
In the middle of the last century, the discovery of a number of cytotoxic agents was an incredible achievement in the treatment of malignant tumors. However, their use was limited by adverse events, primarily the development of myelosuppression. The occurrence of neutropenia is associated with frequent and extremely dangerous events that do not allow timely initiation of a new cycle of therapy and increases risk of infectious complications. Over the years, many attempts have been made to develop optimal management tactics for patients receiving cytotoxic therapy, including antibiotic therapy, the use of nonspecific myelopoiesis modulators, and even blood transfusions. With the advent of granulocyte precursor maturation stimulators in 1983, the situation has improved greatly. Filgrastim and its bioanalogues, registered later, made it possible to reconsider approaches to the use of intensified chemotherapy regimens. It has become possible to control the incidence of neutropenia using only subcutaneous forms of granulocyte colony-stimulating factors (GCSF). The article presents a clinical observation of the use of filgrastim in neoadjuvant therapy of early breast cancer. Filgrastim not only helped to cope with the development of newly diagnosed febrile neutropenia, but during continued treatment it prevented the development of adverse events. The administration of GCSF allowed timely completion of treatment with a complete pathological response, providing the patient with better survival prognosis.
- 25 July 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 124-130
Open AccessThe role of G-CSF in the prevention of cytostaticassociated adverse events during antitumor drug therapy
In the middle of the last century, the discovery of a number of cytotoxic agents was an incredible achievement in the treatment of malignant tumors. However, their use was limited by adverse events, primarily the development of myelosuppression. The occurrence of neutropenia is associated with frequent and extremely dangerous events that do not allow timely initiation of a new cycle of therapy and increases risk of infectious complications. Over the years, many attempts have been made to develop optimal management tactics for patients receiving cytotoxic therapy, including antibiotic therapy, the use of nonspecific myelopoiesis modulators, and even blood transfusions. With the advent of granulocyte precursor maturation stimulators in 1983, the situation has improved greatly. Filgrastim and its bioanalogues, registered later, made it possible to reconsider approaches to the use of intensified chemotherapy regimens. It has become possible to control the incidence of neutropenia using only subcutaneous forms of granulocyte colony-stimulating factors (GCSF). The article presents a clinical observation of the use of filgrastim in neoadjuvant therapy of early breast cancer. Filgrastim not only helped to cope with the development of newly diagnosed febrile neutropenia, but during continued treatment it prevented the development of adverse events. The administration of GCSF allowed timely completion of treatment with a complete pathological response, providing the patient with better survival prognosis.
- Open Access
- 15 December 2021
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 29 (4) , 531-538
Diagnostic potentials of modern radiothermometry in oncomammological practice
Background: Radiothermometry (RTM) is a breast examination method that permits, besides visualization of the pathological foci, to evaluate the quality of metabolism, which is important for the determination of the biological subtypes of breast cancer (BC) and the possibility of the evaluation of the degree of tumor aggressiveness before immunohistochemical analysis. Aim: To study the potentials of modern RTM in the differential diagnosis of benign and malignant breast pathologies and in different biological subtypes of BC. Materials and methods: Overall, 118 patients with different breast pathologies were examined using РТМ 01 РЭС computerized diagnostic complex. Measurements were performed in nine points: directly on the breast ― for the visualization of tumor, in two control points (in the region of the epigastrium and sternal xiphoid process), and in one point in the axillary zone on both sides ― for the identification of probable metastases. The examination time was 1520 min for each woman. RTM results were compared with histological, ultrasound, mammographic, and clinical data. Results: The sensitivity and accuracy of RMT in the differential diagnosis of breast pathology were 96.9% and 74.5%, respectively. The specificity of RTM in the differentiation of aggressive and non-aggressive BC subtypes appeared to be low at 6.6%. In the evaluation of the temperature difference between the pathological and normal tissues, a tendency to a non-increase in the temperature above the tumor in comparison with the unaffected tissue was noted; however, no significant differences between the mean values for the healthy and affected breasts were obtained. No correlations were found between the proliferative index of BC and frequency of thermoasymmetry or extent of its evidence (r 0.3). Conclusion: RTM demonstrated effectiveness in the differential diagnosis of benign and malignant alterations of the breast; thus, it is not a method of choice in the evaluation of the spread and biological subtype of BC.
- 15 December 2021
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 29 (4) , 531-538
Open AccessDiagnostic potentials of modern radiothermometry in oncomammological practice
Background: Radiothermometry (RTM) is a breast examination method that permits, besides visualization of the pathological foci, to evaluate the quality of metabolism, which is important for the determination of the biological subtypes of breast cancer (BC) and the possibility of the evaluation of the degree of tumor aggressiveness before immunohistochemical analysis. Aim: To study the potentials of modern RTM in the differential diagnosis of benign and malignant breast pathologies and in different biological subtypes of BC. Materials and methods: Overall, 118 patients with different breast pathologies were examined using РТМ 01 РЭС computerized diagnostic complex. Measurements were performed in nine points: directly on the breast ― for the visualization of tumor, in two control points (in the region of the epigastrium and sternal xiphoid process), and in one point in the axillary zone on both sides ― for the identification of probable metastases. The examination time was 1520 min for each woman. RTM results were compared with histological, ultrasound, mammographic, and clinical data. Results: The sensitivity and accuracy of RMT in the differential diagnosis of breast pathology were 96.9% and 74.5%, respectively. The specificity of RTM in the differentiation of aggressive and non-aggressive BC subtypes appeared to be low at 6.6%. In the evaluation of the temperature difference between the pathological and normal tissues, a tendency to a non-increase in the temperature above the tumor in comparison with the unaffected tissue was noted; however, no significant differences between the mean values for the healthy and affected breasts were obtained. No correlations were found between the proliferative index of BC and frequency of thermoasymmetry or extent of its evidence (r 0.3). Conclusion: RTM demonstrated effectiveness in the differential diagnosis of benign and malignant alterations of the breast; thus, it is not a method of choice in the evaluation of the spread and biological subtype of BC.